Search
forLearn
5 / 801 resultslearn Prednisolone
learn HYDROXYPROPYLGLUCONAMIDE
learn Kopexil
learn Gluco peptide
Research
5 / 14 resultsresearch Recent advances in the treatment of trichotillomania (hair‐pulling disorder)
New drugs like N-acetylcysteine and dronabinol show promise for treating hair-pulling disorder.
research Treatment of Delusional Infestation with Olanzapine
Olanzapine helped a man who thought he had bugs on his skin.
research Actualización en el tratamiento de la tricotilomanía
N-acetylcysteine and memantine are recommended as safe and effective treatments for trichotillomania.
research Actualización en el tratamiento de la tricotilomanía
Effective treatments for trichotillomania include cognitive-behavioral therapy, certain medications, and alternative support tools.
research Anorexia Nervosa and Gender Dysphoria: A Clinical Case
Eating disorders in gender dysphoria patients may be a coping mechanism for body image issues.
Community Join
5 / 1000+ resultscommunity Positive Hair Result in Patient using Tirzepatide
A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.
community Pyrludimide (KX-826) or Breezula (clascoterone)
The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.
community Xeljanz....the magic drug!!!
A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.
community EMA is re-examining Winlevi (clascoterone at lower concentration)
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
community When will Breezula be released and how does it compare to KX-826?
Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.